BioWorld

June 14, 2004

Cellular Genomics Adds $12.6M To Close Third-Round Financing

Cellular Genomics Inc. padded its Series C financing with an additional $12.6 million, closing the oversubscribed round at $34.9 million. (BioWorld Today) Read More

Momentum Growing For Effort To Legalize Drug Importation

NCI, CMS Begin Initiative To Improve Information On Cancer

Nabi Begins Phase IV Trial To Expand Potential For PhosLo

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...